You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Mometasone furoate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for mometasone furoate and what is the scope of patent protection?

Mometasone furoate is the generic ingredient in eight branded drugs marketed by Organon Llc, Organon, Anda Repository, Cosette, Fougera Pharms, Glenmark Pharms Inc, Taro, Intersect Ent Inc, Encube, Glenmark Pharms Ltd, Padagis Israel, Padagis Us, Torrent, Amneal, Amneal Pharms, Apotex, Aurobindo Pharma, Perrigo Pharma Intl, and Glenmark Speclt, and is included in thirty-two NDAs. There are twenty-eight patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Mometasone furoate has forty-seven patent family members in twelve countries.

There are twenty-seven drug master file entries for mometasone furoate. Twenty-three suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for mometasone furoate

See drug prices for mometasone furoate

Drug Sales Revenue Trends for mometasone furoate

See drug sales revenues for mometasone furoate

Recent Clinical Trials for mometasone furoate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zheng LiuN/A
MEDA Pharma GmbH & Co. KGPhase 2
Morten Hostrup, PhDN/A

See all mometasone furoate clinical trials

Generic filers with tentative approvals for MOMETASONE FUROATE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up0.05MG/SPRAYSPRAY, METERED;NASAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for mometasone furoate
Medical Subject Heading (MeSH) Categories for mometasone furoate
Paragraph IV (Patent) Challenges for MOMETASONE FUROATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NASONEX Nasal Spray mometasone furoate 50 mcg/ Spray 020762 1 2009-08-07
ELOCON Topical Solution (Lotion) mometasone furoate 0.1% 019796 1 2004-06-10

US Patents and Regulatory Information for mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro MOMETASONE FUROATE mometasone furoate CREAM;TOPICAL 076679-001 Dec 21, 2004 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Apotex MOMETASONE FUROATE mometasone furoate SPRAY, METERED;NASAL 091161-001 Mar 22, 2016 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal Pharms MOMETASONE FUROATE mometasone furoate SPRAY, METERED;NASAL 207989-001 Apr 3, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon ELOCON mometasone furoate LOTION;TOPICAL 019796-001 Mar 30, 1989 ⤷  Sign Up ⤷  Sign Up
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 ⤷  Sign Up ⤷  Sign Up
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for mometasone furoate

Country Patent Number Title Estimated Expiration
Australia 2006231506 Device and methods for treating paranasal sinus conditions ⤷  Sign Up
China 112089505 用于治疗鼻窦病状的系统、装置以及方法 (Systems, devices, and method for treating a sinus condition) ⤷  Sign Up
European Patent Office 1605863 ADMINISTRATION DANS UN SINUS D'AGENTS THERAPEUTIQUES A LIBERATION PROLONGEE (SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for mometasone furoate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3043773 2190041-0 Sweden ⤷  Sign Up PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; NAT. REG. NO/DATE: MT NR 60226 20210519; FIRST REG.: AT APPROVAL NR 140638 20210426
0548114 SPC/GB97/064 United Kingdom ⤷  Sign Up PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
3043773 132021000000191 Italy ⤷  Sign Up PRODUCT NAME: MOMETASONE O UN SUO SALE E OLOPATADINA O UN SUO SALE(RYALTRIS); AUTHORISATION NUMBER(S) AND DATE(S): 048499014, 048499026, 048499038, 20210726;140638, 20210426
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.